CARA - Cara Therapeutics, Inc.
| Previous Close | 16.89 |
| Open | 17.05 |
| Bid | 17.33 x 900 |
| Ask | 17.33 x 800 |
| Day's Range | 16.93 - 17.36 |
| 52 Week Range | 14.10 - 27.55 |
| Volume | 664,603 |
| Avg. Volume | 711,265 |
| Market Cap | 807.78M |
| Beta (5Y Monthly) | 2.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 |
| Earnings Date | Nov 04, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.89 |
- Yahoo Finance Video
First cannabis cafe in the U.S. opens in Los Angeles
"Lowell Herb Co." is launching the nation's first ever cannabis cafe. Backed by Miley Cyrus, the cafe gives its customers a place to legally purchase and consume cannabis products. Lowell Herb Co.'s Director Kevin Brady joins Yahoo Finance's Zack Guzman and Heidi Chung, along with “The Morning Brew” Business Editor and Podcast Host Kinsey Grant, to discuss.
- Investopedia
New Cannabis Products Which Could Disrupt the Industry in 2020
The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.
- GlobeNewswire
Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 08, 2020 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
- Insider Monkey
Was Smart Money Right About Piling Into Cara Therapeutics Inc (CARA) in September?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- GlobeNewswire
Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock, to be distributed among two new non-executive employees, pursuant to Cara’s 2019 Inducement Plan. The awards have a grant date of December 2, 2019 and an exercise price of $25.88 per share, which is equal to the closing price of Cara’s common stock on the date of grant. The stock options were granted as inducement material to each new employee entering into employment with Cara in accordance with Nasdaq Listing Rule 5635(c)(4).
- Thomson Reuters StreetEvents
Edited Transcript of CARA earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Cara Therapeutics Inc Earnings Call
- Zacks
Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
- Simply Wall St.
Investors Who Bought Cara Therapeutics (NASDAQ:CARA) Shares Three Years Ago Are Now Up 78%
Shareholders of Cara Therapeutics, Inc. (NASDAQ:CARA) might have been startled to see the share price drop -35% in...
- GlobeNewswire
Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
STAMFORD, Conn., Dec. 03, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
- Benzinga
Benzinga Pro's Top 6 Stocks To Watch For Tues., Dec. 3, 2019: CARA, VRAY, LE, KOD, FXI, ROKU
Benzinga Pro's Stocks To Watch For Tuesday Cara Therapeutics (CARA) - The company announced the Phase 2 trial of oral KORSUVA achieved the primary endpoint but did not achieve statistical significance ...
- MarketWatch
UPDATE: Cara Therapeutics announces positive results in trial of treatment for chronic kidney disease
Cara Therapeutics Inc. announced positive results Tuesday from a mid-stage trial of a treatment of pruritis in patients with chronic kidney disease (CKD), an itchiness associated with the kidney disorder. The company said the phase 2 trial of oral Korsuva met its primary endpoint with a statistically significant reduction in worst itching intensity scores with 1 mg tablet strength versus placebo after 12 weeks of treatment. "CKD-associated pruritus remains a significant unmet need for approximately one-third of diagnosed CKD patients in the U.S.," Cara Chief Executive Derek Chalmers said in a statement. Abut 30 million Americans suffer from CKD, according to the Centers for Disease Control and Prevention. Cara is planning to hold a conference call at 8.30 a.m. Eastern on Tuesday. Shares fell 23% premarket after resuming trade following a halt for the news, but have gained 99% in 2019, while the S&P 500 has gained 25%.
- GlobeNewswire
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period.
- Zacks
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?
Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.
- GlobeNewswire
Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn., Nov. 12, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.
- GlobeNewswire
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the New England Journal of Medicine (NEJM) published full results from the randomized, double-blind pivotal Phase 3 (KALM-1) trial of difelikefalin (KORSUVA™ Injection) in patients undergoing hemodialysis with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The paper, titled “A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus,” summarizes data from 378 patients, randomized to receive intravenous bolus difelikefalin at a dose of 0.5 mcg/kg or placebo at the end of each dialysis session, administered over a 12-week treatment period.
- Zacks
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -25.42% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cara Therapeutics Reports Third Quarter 2019 Financial Results
STAMFORD, Conn., Nov. 05, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed.
- GlobeNewswire
Cara Therapeutics Announces Presentations at Kidney Week 2019
STAMFORD, Conn., Nov. 01, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Insider Monkey
Here’s What Hedge Funds Think About Cara Therapeutics Inc (CARA)
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- GlobeNewswire
Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019
STAMFORD, Conn., Oct. 29, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Zacks
Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investopedia
Top Marijuana Stocks on the NASDAQ
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
- Simply Wall St.
Have Insiders Been Selling Cara Therapeutics, Inc. (NASDAQ:CARA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- GlobeNewswire
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced the completion of an interim statistical assessment of its pivotal KALM-2 Phase 3 global clinical trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Based on the Independent Data Monitoring Committee’s (IDMC) recommendation, the size of the trial will be increased by approximately 20 percent, from an original enrollment target of 350 patients to 430 patients, to maintain the pre-specified statistical power of 90 percent or greater on the trial’s primary endpoint.
- GlobeNewswire
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
STAMFORD, Conn., Sept. 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
